Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 174

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 174
---
trunner, the FDA’s effort to shift cancer 
 therapeutics development in earlier lines of therapy.                                                                                                                                                                                                                                                                                                                                                                                 |

| • |     | We utilize an efficient virtual model with outsourced clinical development and manufacturing. We                                                                                                                                                                                                                                                                                
 plan to utilize an outsourced model for research, development and manufacturing operations. Initially, we intend to continue to benefit from the continuity of partnership with WuXi Biologics and Hangzhou DAC for near-term IND-enabling studies and ADC manufacturing. We will expand our CRDMO network as appropriate as our portfolio advances further in clinical trials. |

| • |     | We look to continue to build our portfolio through strategic partnerships. We plan to continue to                                                                        
 use our management and board expertise, as well as our extensive network, to maximize and grow our portfolio through additional strategic partnerships and transactions. |

Our Portfolio We were deliberate in identifying promising tumor targets that are broadly expressed across multiple cancer types, and plan to focus our initial development efforts on high potential indications where first generation ADCs against these targets have already shown proof of concept in Phase 1 clinical trials. The three tumor targets we selected – PTK7, MUC16 and SEZ6 – are each validated by a first generation ADC that demonstrated promising efficacy in key indications, but were discontinued, largely due to safety and limited therapeutic index. Importantly, we prioritized the ability to be in the clinic quickly, and we expect to file INDs in the next 12 to 24 months, starting with our PTK7-directed asset in the second half of 2025, followed closely by the MUC16-directed asset by the end of 2025, and the SEZ6-directed asset in mid-2026.

| • |     | PTK7-CPT113 presents a differentiated opportunity to be among the first next wave ADCs in clinical                 
 development for high PTK7 expressing cancers, including NSCLC, ovarian cancer and several other major indications. |

| • |     | mMUC16-CPT113 is potentially the first ADC that targets membrane-bound portion of MUC16, a                                                   
 glycoprotein often overexpressed in cancers of female origin, such as ovarian cancer, endometrial cancer, cervical cancer, or breast cancer. |

| • |     | biSEZ6-CPT113 is designed to bind to two epitopes on the target SEZ6, which is often                                                                          
 overexpressed in cancers of neuroendocrine origin. We believe this biparatopic approach can potentially improve internal